My site

INGELHEIM, Germany - Monday, December 10th 2012 [ME NewsWire]

    In RE-LY®, patients had better survival prognosis and spent less time in intensive care following a major bleed with Pradaxa® (dabigatran etexilate) than with warfarin
    Data provide further support for the favourable safety profile of Pradaxa®
    Presentation at American Society of Hematology (ASH) 2012 highlighted as ‘Best of ASH’

(BUSINESS WIRE)-- For Non-US, Non-UK & Non-Canadian Media Only

Results from a new post-hoc analysis of the landmark RE-LY®i trial show that in patients experiencing a major bleeding event, treatment with Pradaxa® (dabigatran etexilate) was associated with lower mortality and a shorter length of stay in intensive care compared to warfarin. In a pooled post-hoc analysis of five Phase III trials with Pradaxa®, the data show a clear trend towards a better prognosis after a major bleed with Prada ... Read more »

ME Newswire / Business Wire

VILLEJUIF, France - Monday, December 10th 2012

Worldwide Innovative Network (WIN) in personalized cancer medicine consortium today proudly announced that Pfizer, Inc(NYSE:PFE) is the first pharmaceutical company to become a member of the consortium. Founded on the recognition that greater success can be achieved through collaboration than any organization can achieve alone, the WIN Consortium is a global network of leading academic, industry, and patient advocacy organizations working to make personalized cancer care a reality for patients worldwide.

Pfizer’s strong corporate commitment to the development of drugs using a precision medicine approach, coupled with the company’s deep breadth of experience in the development of oncology therapeutics, strategically align the company’s goals and capabilities with the mission of the WIN Consortium. As the newest member of the consortium, Pfizer will play an integral role in shaping the future ... Read more »

ATLANTA - Sunday, December 9th 2012 [ME NewsWire]

MLN9708: First oral proteasome inhibitor to enter clinical evaluation in front-line multiple myeloma in combination with lenalidomide, dexamethasone

(BUSINESS WIRE)-- Millennium: The Takeda Oncology Companywith its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today reported data from a phase 1 / 2 study of once a week investigational MLN9708 in combination with standard dose lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (MM). The previously reported phase 1 portion of the study was a dose escalation study to determine the safety, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of MLN9708 in combination with lenalidomide and dexamethasone. The primary objectives of the ongoing phase 2 portion of the study are to determine the combined complete and very good partial response rates (≥VGPR), safety and tolerability. Secondary objectives include overall resp ... Read more »